| http://purl.uniprot.org/citations/31085718 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/31085718 | http://www.w3.org/2000/01/rdf-schema#comment | "The specific functions and clinical significance of miR-940 in endometrial carcinoma (EC) have not been studied. First, we assessed the expression of miR-940 and MRVI1 in EC tissues collected from The Cancer Genome Atlas (TCGA) database and EC cell lines. miR-940 was significantly overexpressed in EC tissues and cell lines, particularly in RL95-2 cells. Correlation analysis showed that miR-940 expression level was remarkably associated with age, grade, and death. Moreover, the overall survival (OS) rate in the miR-940 low expression group was higher, compared with miR-940 high expression group. Univariate and multivariate models demonstrated that miR-940 expression, stage, and age were predictive indicators of OS. Moreover, there was no significance of the proliferation ability among the three EC cell lines (RL95-2, ISK, and KLE). To reveal the biological roles of miR-940, we respectively transfected RL95-2 cells with miR-940 mimics, miR-940 inhibitors, and control to further investigate the cell proliferation ability, and migration as well as invasion potential of RL95-2 cells. The transfection of miR-940 mimics significantly increased the proliferation and migration/invasion ability of RL95-2 cells. MRVI1 was predicted to be a potential target of miR-940 by means of in silico analysis followed by validation using luciferase reporter assays. MRVI1 was correlated with good prognosis. Moreover, forced expression of MRVI1 in miR-940 mimic transfected cells abolished the facilitation of miR-940 on cell proliferation, migration, and invasion of RL95-2 and KLE cells. In conclusion, our study demonstrates that miR-940 might function as a reliable diagnostic and prognostic signature in EC."xsd:string |
| http://purl.uniprot.org/citations/31085718 | http://purl.org/dc/terms/identifier | "doi:10.1042/bsr20190077"xsd:string |
| http://purl.uniprot.org/citations/31085718 | http://purl.uniprot.org/core/author | "Zhou Z."xsd:string |
| http://purl.uniprot.org/citations/31085718 | http://purl.uniprot.org/core/author | "Kong Y."xsd:string |
| http://purl.uniprot.org/citations/31085718 | http://purl.uniprot.org/core/author | "Wang L.J."xsd:string |
| http://purl.uniprot.org/citations/31085718 | http://purl.uniprot.org/core/author | "Xu Y.P."xsd:string |
| http://purl.uniprot.org/citations/31085718 | http://purl.uniprot.org/core/date | "2019"xsd:gYear |
| http://purl.uniprot.org/citations/31085718 | http://purl.uniprot.org/core/name | "Biosci Rep"xsd:string |
| http://purl.uniprot.org/citations/31085718 | http://purl.uniprot.org/core/pages | "BSR20190077"xsd:string |
| http://purl.uniprot.org/citations/31085718 | http://purl.uniprot.org/core/title | "miR-940 potentially promotes proliferation and metastasis of endometrial carcinoma through regulation of MRVI1."xsd:string |
| http://purl.uniprot.org/citations/31085718 | http://purl.uniprot.org/core/volume | "39"xsd:string |
| http://purl.uniprot.org/citations/31085718 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/31085718 |
| http://purl.uniprot.org/citations/31085718 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/31085718 |
| http://purl.uniprot.org/uniprot/#_B7Z715-mappedCitation-31085718 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/31085718 |
| http://purl.uniprot.org/uniprot/#_Q9Y6F6-mappedCitation-31085718 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/31085718 |
| http://purl.uniprot.org/uniprot/Q9Y6F6 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/31085718 |
| http://purl.uniprot.org/uniprot/B7Z715 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/31085718 |